ITM Isotope Technologies Munich SE: ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

Enhancement of ITM's development and manufacturing activities strengthens ITM's position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 - ITM Isotope

Related Keywords

Munich ,Bayern ,Germany ,Garching ,Switzerland ,Swiss ,Steffen Schuster ,Julia Hofmann Svenja ,Ben Orzelek ,Roger Schibli ,Group Leader ,Research Group Leader ,Head Of The Center ,Corporate Communications ,European Journal Of Nuclear Medicine ,Paul Scherrer Institute ,Targeted Radionuclide Therapy ,Technologies Munich ,Radiopharmaceutical Science ,Radionuclide Therapy ,European Journal ,Nuclear Medicine ,Molecular Imaging ,Isotope ,Technologies ,Centers ,Cooperation ,Agreement ,Paul ,Scherrer ,Institute ,Development ,Upscaled ,Manufacturing ,Tterbium ,Heranostic ,Application ,Dancer ,